Related Experiment Video

Updated: Jun 23, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives

Dirk Sander1, Mark T Kearney

  • 1Department of Neurology, Medical Park Hospital, Thanngasse 15, 83483 Bischofswiesen, Germany. d.sander@mac.com

Journal of Neurology
|April 29, 2009
PubMed

Insights

Type 2 diabetes significantly increases stroke risk, particularly recurrent events. Current treatments targeting metabolic factors and thrombotic risk show limited efficacy, necessitating new therapeutic strategies for stroke prevention in this population.

Area of Science:

  • Neurology
  • Endocrinology
  • Cardiovascular Medicine

Background:

  • Patients with type 2 diabetes face a high risk of cerebrovascular events, especially recurrent strokes.
  • Traditional risk factor management (hypertension, dyslipidemia, hyperglycemia) has not adequately reduced this excess risk.
  • Thrombotic risk agents are understudied for stroke prevention in diabetic populations.

Purpose of the Study:

  • To systematically review existing literature on therapeutic interventions for stroke in type 2 diabetes.
  • To evaluate the impact of current treatments on stroke risk, including primary and secondary prevention.
  • To identify gaps in evidence and highlight potential strategies for improving outcomes.

Main Methods:

  • Systematic literature review of published studies.
  • Analysis of evidence on interventions for stroke prevention and management in type 2 diabetes.
  • Assessment of impact on cerebrovascular event risk.

Main Results:

  • Current interventions targeting metabolic risk factors have failed to eliminate the excess stroke risk in type 2 diabetes.
  • Evidence supporting the efficacy of interventions for secondary stroke prevention in this group is limited.
  • There is a notable lack of prospective data on effective treatments.

Conclusions:

  • Reducing cerebrovascular burden in type 2 diabetes remains a significant challenge.
  • New therapeutic approaches for primary and secondary stroke prevention, as well as acute stroke management, are urgently needed.
  • Rigorous evaluation of novel strategies is essential to improve outcomes for patients with type 2 diabetes and stroke.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...